Trials / Recruiting
RecruitingNCT07269210
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solbinsiran | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-12-08
- Primary completion
- 2027-03-01
- Completion
- 2027-08-01
- First posted
- 2025-12-08
- Last updated
- 2026-03-20
Locations
40 sites across 4 countries: United States, Canada, China, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07269210. Inclusion in this directory is not an endorsement.